Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06605430 · ClinicalTrials.gov registry record · Phase 2
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
A Phase 2 study of Colorectal Cancer Metastatic and Pancreatic Cancer Metastatic, sponsored by HealthPartners Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06605430 is a Phase 2 study of Colorectal Cancer Metastatic and Pancreatic Cancer Metastatic that is actively recruiting participants, run by HealthPartners Institute. The registered enrollment target is 64 participants, below the 202-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06605430, a Phase 2 study of Colorectal Cancer Metastatic and Pancreatic Cancer Metastatic, is actively recruiting participants, sponsored by HealthPartners Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of life, decrease their ability to tolerate cancer treatments, and lead to worse survival. Current approaches to manage these cancer-associated symptoms often work poorly, with most patients reporting a moderate to severe symptom burden. Therefore, there is an urgent need for treatments that improve these symptoms in patients with advanced pancreatic and colorectal cancer, and data suggests that medical cannabis can help. In this research study, we are examining the usefulness of using medical cannabis in patients with advanced pancreatic cancer and colorectal cancer to further study how cannabis can impact their symptom burden.
Conditions Studied
Interventions
- DRUG Medical Cannabis
Study Locations (1)
Minnesota
- HealthPartners Cancer Research Center - Saint Louis Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06605430
The ClinicalTrials.gov registry entry for NCT06605430 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (68% lower). The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Colorectal Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which Medical Cannabis is the first listed.
NCT06605430 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06605430 about?
NCT06605430 is a clinical study titled "Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer". Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of life, decrease their ability to tolerate cancer treatments, and lead to wo...
What is the current status of trial NCT06605430?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2024-09-16. Estimated completion is 2026-12.
What conditions does trial NCT06605430 study?
This clinical trial studies the following conditions: Colorectal Cancer Metastatic, Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable.
What interventions are being tested in trial NCT06605430?
The interventions under investigation include: Medical Cannabis (DRUG).
Who is sponsoring clinical trial NCT06605430?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06605430 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
RECRUITING · Phase 2
-
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
RECRUITING · Phase 2
-
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
RECRUITING · Phase 2
-
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
ACTIVE NOT RECRUITING · Phase 2
-
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
COMPLETED · Phase 2
-
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.